HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IMRX
Immuneering Corporation
There isn't enough reported data to score IMRX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IMRX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
IMRX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IMRX PE Valuation
IMRX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IMRX Forward outlook
There aren't enough analyst estimates for IMRX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
IMRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.14 | +$0.65 |
| Q2 2026 | -$1.15 | +$0.75 |
| Q1 2026 | -$1.28 | +$0.69 |
| Q4 2025 | -$1.49 | +$0.55 |
| Q3 2025 | -$1.79 | +$0.17 |
| Q2 2025 | -$1.90 | $0.00 |
| Q1 2025 | -$1.97 | -$0.11 |
| Q4 2024 | -$2.04 | -$0.16 |
IMRX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for IMRX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IMRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2022 | $455 | -100% |
| Q3 2022 | $38.4K | -92% |
| Q2 2022 | $94.4K | -86% |
| Q1 2022 | $183.7K | -75% |
| Q4 2021 | $189.6K | -71% |
| Q3 2021 | $482.1K | -29% |
| Q2 2021 | $660K | +37% |
| Q1 2021 | $748.2K | +55% |
IMRX's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2022 | -3073628% | -3067765 points |
| Q3 2022 | -34362% | -32590 points |
| Q2 2022 | -12334% | -11124 points |
| Q1 2022 | -7036% | -6203 points |
| Q4 2021 | -5863% | -4986 points |
| Q3 2021 | -1772% | -1127 points |
| Q2 2021 | -1211% | -461 points |
| Q1 2021 | -833% | -163 points |
IMRX's operating margin was −3073628% last quarter, down 3067765 points from the same quarter a year ago, near the bottom of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IMRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$16.8M | -$4.8M |
| Q2 2026 | -$16.5M | -$7.1M |
| Q1 2026 | -$18.5M | -$4.4M |
| Q4 2025 | -$10M | +$4.6M |
| Q3 2025 | -$12M | +$1.5M |
| Q2 2025 | -$9.4M | +$2.1M |
| Q1 2025 | -$14.1M | +$1.4M |
| Q4 2024 | -$14.5M | -$2.6M |
IMRX has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IMRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IMRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +17K shares |
| 1 year | +63% | +25M shares |
| 3 years | +121% | +35.4M shares |
| 5 years | +1206% | +59.8M shares |
| Available history | +379% | +51.2M shares |
IMRX has 65M diluted shares, up 63% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IMRX Net Leverage
IMRX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IMRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.9 | Neutral |
| Stochastic | 16.4 | Oversold |
IMRX's weekly RSI is 39 (neutral) and its Stochastic is 16 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IMRX PE vs Healthcare Sector
IMRX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IMRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.84 | 4.4% below |
| 20 week MA | $4.38 | 16% below |
| 50 week MA | $4.91 | 25% below |
| 100 week MA | $4.24 | 13% below |
| 200 week MA | $4.78 | 23% below |
IMRX is in a downtrend: it's below all five of its weekly moving averages, and 23% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over IMRX on returns for 2026, with the stronger performance.
IMRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $17.6 | $20.5 | +17% |
| 2022 | $20.5 | $4.37 | -79% |
| 2023 | $4.37 | $7.35 | +68% |
| 2024 | $7.35 | $2.33 | -68% |
| 2025 | $2.33 | $6.73 | +189% |
| 2026 YTD | $6.73 | $3.67 | -45% |
IMRX's yearly returns have swung widely, from +189% in 2025 to −79% in 2022. It's down 45% so far in 2026.